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Abstract.
This

thesis

examines

the

synthesis

of

a

library

of

benzyl-

and

bisbenzylisoquinolines (BBI) derivatives based on the reticuline motif. These
compounds were assessed for their; i) cytotoxicity on 3 cancer cell lines, ii) activity on
HIV-infected cells, iii) antibacterial activity, and iv) CNS receptor binding affinities.
Chapter 2 describes the employment of palladium-catalysed Stille, Heck and
Sonogashira coupling reactions to synthesise a library of BBI derivatives. 2’-Vinyl(67), 2’-allyl- (68) and 2’-iodo (58) derivatives of racemic, N-TFA protected,
norlaudanosine were used as the key building blocks in this investigation. The key 2’vinyl- and 2’-allyl-norlaudanosine derivatives 67 and 68, respectively were readily
prepared

from

palladium-catalysed

Stille

coupling

reactions

of

the

2’-

iodonorlaudanosine derivative 58 and vinyl- or allyl-tributylstannane. The Heck
coupling reactions between the 2’-vinyl-norlaudanosine derivative 67 and the 2’-iodonorlaudanosine derivative 58 gave not only the desired stilbene BBI derivative 65 but
also the unexpected 1,1-disubstituted regioisomer 69. This unexpected regioisomer was
a result of the electron rich nature of both stating materials that favoured a cationic
palladium intermediate. The best Heck coupling reaction conditions involved the use of
Pd(OAc)2, DMG, NaOAc and NMP at 130 0C. These conditions gave the highest yield
and the best regioisomer selectively in favour of the BBI derivative 65. Fortunately
these regioisomers were readily separated by triturating the product mixture with
methanol. The Heck coupling reaction between the 2’-allylnorlaudanosine derivative 68
and the aryl iodide 58 successfully afforded the three carbon tethered BBI derivative 66
in moderate yield.
It was found, however, that these Heck coupling reaction conditions were only
efficient with aryl iodide precursors. This was evident from the attempted
xxviii

intramolecular Heck coupling reactions on the aryl bromide precursor 89, to give the
macrocyclic BBI derivative 88. The optimised Heck coupling reaction conditions failed
to produce the desired product, while more traditional Heck coupling conditions gave
the required product in poor yield (15 %).
The unsaturated BBI derivative 65 and its regioisomer 69 were subjected to
hydrogenation conditions over Pd/C under a hydrogen atmosphere. However, the
regioisomer 69 was found to be too sterically hindered and did not undergo the
hydrogenation reaction, while derivative 65 encountered solubility problems and only
rac-65 underwent the hydrogenation reaction to give rac-80, leaving the less soluble
meso-65 intact. The compounds rac-80 and meso-65 were readily separated by column
chromatography.
Chapter 2 also described the successful synthesis of the targeted acetylinic BBI
derivative 63 via coupling of the 2’-ethynylbenzylisoquinoline derivative 84 with the
aryl iodide 58, using a Pd/Cu catalysed Sonogashira coupling reaction, followed by NTFA deprotection of the N-TFA 2’-ethynylbenzylisoquinoline derivative 83.
The synthesis of a library of 2’-arylvinyl- and 2’-arylallyl-benzylisoquinolines
derivatives using the optimised Heck coupling reaction conditions developed in Chapter
2 is described in Chapter 3. This set of compounds included benzylisoquinolines having
either an exocyclic N,N-dimethylamino (92-103) or N-acetamido (104-107) substituent.
A third group of compounds (108-111) in this set had the exocyclic amino or amido
group completely excluded. It was found that the Heck coupling reaction of the 2’vinyllaudanosine derivative 67 and the aryl iodides 118, 119, 131 and 135 afforded only
one regioisomer, unlike the Heck coupling between 67 and 58 in Chapter 2, which gave
the two regioisomers 65 and 69. The Heck coupling reactions between the 2’allyllaudanosine derivative 68 and the aryl iodides 118, 119, 131 and 135 gave two
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regioisomers 115a,b; 116a,b; 129a,b and 137a,b, respectively, due to two possible sites
of palladium hydride elimination.
In Chapter 4, the use of the ruthenium-catalysed CM and RCM reactions toward
the successful synthesis of the four carbon tethered BBI derivatives, 138-142, in both
unsaturated and saturated forms (via hydrogenation reactions) was described. The
synthesis of the analogous two and three carbon tethered BBI derivatives via this
method proved less efficient.
Chapter 5 reported the synthesis of a library of aminoalkyl benzylisoquinoline
derivatives, incorporating both cyclic and acyclic amines (155-162). These analogues
were obtained by a simple reductive amination methodology involving the reaction of
commercially available amines with the aldehydes 186 and 187, which were generated
from the 2’-vinyl- and 2’-allyllaudanosine derivatives 67 and 68, respectively. The
initially planned pathway to one of these aldehydes involved the rearrangement of the
epoxide 188, however this epoxide was too unstable under the reaction conditions and
readily underwent ring opening with m-chlorobenzoic acid. An alternative pathway
using oxidative cleavage of the diols 190 and 191, which were generated from
dihydroxylation of the 2’-vinyl- and 2’-allyllaudanosine derivatives, 67 and 68,
respectively, was found to be more successful for the synthesis of these aldehydes.
Chapter 5 also described the synthesis of an additional class of aminoalkyl
benzylisoquinoline derivatives, 163 and 164, containing a β-amino alcohol moiety.
Retro-synthetic analysis showed two possible synthetic pathways which were either via
the ring opening of the cyclic sulfates 195 and 196 or via the nucleophillic displacement
of the tosylates 197 and 198 with an amine nucleophile. The latter pathway proved more
successful and afforded the β-amino alcohol derivatives 163 and 164, however, the
yields of these reactions should be optimised in future studies.
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The synthesis of the benzylisoquinoline derivatives containing a nine- and tenmembered heterocylic ring, 165-167, was also described in Chapter 5. The synthesis of
these analogues was initially attempted via the intramolecular reductive amination
reaction between an aldehyde moiety at the C2’ position of 219 and its free isoquinoline
amino group. However, the synthesis of the aldehyde moiety via the hydrolysis of its
protected diacetal form was very difficult; therefore an alternative synthesis was
developed. This method involved an intramolecular nucleophilic displacement of the
chloride of the α-chloroacetamides 214 and 215 by the free isoquinoline amino moiety.
This method successfully afforded the nine- and ten-membered ring benzylisoquinoline
derivatives 165 and 167 in moderate yields (42-57 %). Lithium aluminium hydride
reduction of 165 gave the corresponding cyclic diamino derivative 166 in high yield.
Some of the benzyl- and bis-benzylisoquinoline derivatives reported in Chapters
2-5 were sent for biological testing for their cytotoxicity on 3 cancer cell lines, activity
on HIV-infected cells, their antibacterial activity and CNS receptor binding affinities.
The BBI derivatives showed higher activity on cancer cell lines than the corresponding
benzylisoquinoline derivatives. Various BBI and benzylisoquinoline derivatives have
showed promising CNS-receptor binding affinities, especially for 5HT receptors and
more prominently on the 5-HT1B, 5-HT2A and 5-HT7 receptors. At this stage, a clear
structure-activity trend could not be discerned and the mode of action of these
analogues was not clear. Further results on the awaiting analogues may help to develop
pharmacophore models for CNS active compounds in the future, and eventually, allow
the design and development of more selective and potent ligands.
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